Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TT5RWKQ)

DTT Name Immunoglobulin gamma Fc receptor IIB (FCGR2B)
Synonyms Low affinity immunoglobulin gamma Fc region receptor II-b; IgG Fc receptor II-b; FcRII-b; Fc-gamma-RIIb; Fc-gamma RII-b; FCG2B; CDw32 B; CD32 B
Gene Name FCGR2B
DTT Type
Clinical trial target
 [1]
BioChemical Class
Immunoglobulin
UniProt ID
FCG2B_HUMAN
TTD ID
T03573
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
Sequence
MGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWIN
VLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSL
SDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPN
FSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAA
VVALIYCRKKRISALPGYPECREMGETLPEKPANPTNPDEADKVGAENTITYSLLMHPDA
LEEPDDQNRI
Function
Receptor for the Fc region of complexed or aggregated immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B-cells. Binding to this receptor results in down-modulation of previous state of cell activation triggered via antigen receptors on B-cells (BCR), T-cells (TCR) or via another Fc receptor. Isoform IIB1 fails to mediate endocytosis or phagocytosis. Isoform IIB2 does not trigger phagocytosis.
KEGG Pathway
Phagosome (hsa04145 )
Osteoclast differentiation (hsa04380 )
B cell receptor signaling pathway (hsa04662 )
Fc gamma R-mediated phagocytosis (hsa04666 )
Staphylococcus aureus infection (hsa05150 )
Tuberculosis (hsa05152 )
Measles (hsa05162 )
Reactome Pathway
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell (R-HSA-198933 )

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
3 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Xmab 5871 DMLIPY1 Autoimmune diabetes 5A10 Phase 2 [1]
BI 1206 DMTOMWB B-cell lymphoma 2A86 Phase 1/2 [2]
MGD010 DMA368V Autoimmune disease 4A40-4A45 Phase 1 [3]
------------------------------------------------------------------------------------

References

1 CD19 as an attractive target for antibody-based therapy. MAbs. 2012 Sep-Oct;4(5):571-7.
2 Clinical pipeline report, company report or official report of BioInvent.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)